Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. & MIAMI Clinical Studies of EIDD-2801 for the Treatment of Patients…
Dateline City: KENILWORTH, N.J. & NEW YORK New Collaboration to Leverage Complementary Expertise and Capabilities…
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone…
Dateline City: KENILWORTH, N.J. & PITTSBURGH Agreement Includes Strategic Investments from UPMC Enterprises and Merck…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA…
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced…
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
Dateline City: MADISON, N.J. Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal…
Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
Dateline City: KENILWORTH, N.J. U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental…
Dateline City: KENILWORTH, N.J. Merck is Proud to Make New Commitment in Support of #GivingTuesdayNow…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%;…
Dateline City: KENILWORTH, N.J. Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six…
Dateline City: KENILWORTH, N.J. & SEATTLE KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
.jpg)
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
Dateline City: KENILWORTH, N.J. Additional sBLAs Filed Across All Approved Adult Indications KENILWORTH, N.J.–(BUSINESS WIRE)–Merck…
Dateline City: KENILWORTH, N.J. Support is Available for Eligible U.S. Patients Who Have Lost Their…
.jpg)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH,…
Dateline City: KENILWORTH, N.J. New Merck for Mothers Commitment Adds to Merck’s Overall Support to…
Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients…
Dateline City: KENILWORTH, N.J. First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. & NEW YORK & INDIANAPOLIS Three leading biopharmaceutical companies have announced…
Dateline City: KENILWORTH, N.J. Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused…
Dateline City: KENILWORTH, N.J. Merck is Contributing 300,000 Masks to New Jersey’s Office of Homeland…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–In response to the calls for personal protective equipment…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE:MRK), known as MSD outside…
Dateline City: KENILWORTH, N.J. Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour…
Dateline City: KENILWORTH, N.J. The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival…
Dateline City: KENILWORTH, N.J. & MELBOURNE, Australia Preclinical Data on Candidate Anti Malaria Agents Published…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Democratic Republic of the Congo One of the First African Countries…
Dateline City: KENILWORTH, N.J. In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved…
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2019 Worldwide Sales Were $11.9 Billion, an Increase of 8%;…